Eyenovia. has been granted a patent for a method and device that utilizes a charge isolated ejector mechanism to deliver low dosage volume medicaments directly to the eye. This technology aims to enhance the precision and effectiveness of ophthalmic fluid delivery through controlled droplet generation. GlobalData’s report on Eyenovia gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Eyenovia, Ultrasonic atomizers was a key innovation area identified from patents. Eyenovia's grant share as of June 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Ophthalmic drug delivery using a charge isolated ejector mechanism
The patent US12029682B2 outlines a method for delivering a low dosage volume medicament composition directly to the eye of a subject, utilizing a charge isolated ejector mechanism. This method involves generating a directed stream of droplets containing the medicament, which is specifically designed to deposit on the cornea. The ejector mechanism is characterized by a piezoelectric actuator that oscillates a generator plate with multiple openings, facilitating the precise delivery of droplets. The claims specify that the volume of medicament delivered can be as low as 6 microliters, significantly less than the volume typically dispensed by standard eyedroppers. The method aims to ensure that at least 75% of the droplet mass effectively reaches the cornea, with droplet diameters ranging from 20 to 400 microns and initial velocities between 0.5 m/s and 10 m/s.
Additionally, the patent identifies specific medicaments suitable for this delivery method, including various glaucoma treatments such as travoprost and latanoprost. The claims further elaborate on the structural components of the charge isolated ejector mechanism, which includes a flexible printed circuit with a laminate structure that separates the piezoelectric actuator from other components to maintain charge isolation. The design also incorporates an ejector plate that enhances the delivery process without obstructing the droplet formation. Overall, this patent presents a novel approach to ocular drug delivery, focusing on efficiency and precision in treating eye conditions, particularly glaucoma.
To know more about GlobalData’s detailed insights on Eyenovia, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
